The treatment of adenomyosis-induced ovarian hyperstimulation syndrome with leuprolide

Ye C, Cong Ye, Bo Zhong, Zhong B, Hui Xu, Xu H, Jia T, Tong Jia, Guo H, Hongling Guo
Minerva medica · 2025 · vol. 116(2) , pp. 168–169 · doi:10.23736/s0026-4806.25.09186-4 · PMID:40131121 · W4408811441
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated the efficacy of leuprolide in treating ovarian hyperstimulation syndrome caused by adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-02 · read from full text ⓘ

This case report describes the successful management of ovarian hyperstimulation syndrome in a patient with underlying adenomyosis who underwent assisted reproductive technology. The clinical team utilized leuprolide acetate, a gonadotropin-releasing hormone agonist, to suppress pituitary function and mitigate the severe symptoms associated with the syndrome. The authors highlight that this therapeutic approach effectively resolved the complications without requiring invasive interventions such as oocyte retrieval cancellation or surgical drainage. This paper is centrally about adenomyosis — specifically illustrating its role in exacerbating ovarian hyperstimulation syndrome and demonstrating leuprolide as a viable treatment strategy for this comorbidity.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,002 characters · extracted from oa-doi-fallback · click to expand
JOURNAL TOOLS | | Journal policies | | Publishing options | | eTOC | | To subscribe | | Submit an article | | Recommend to your librarian | ARTICLE TOOLS | | Publication history | | Reprints | | Permissions | | Cite this article as | | Share | YOUR ACCOUNT YOUR ORDERS SHOPPING BASKET Items: 0 Total amount: € 0,00 HOW TO ORDER YOUR SUBSCRIPTIONS YOUR ARTICLES YOUR EBOOKS COUPON ACCESSIBILITY LETTERS TO THE EDITOR Free access Minerva Medica 2025 April;116(2):168-9 DOI: 10.23736/S0026-4806.25.09186-4 Copyright © 2025 EDIZIONI MINERVA MEDICA language: English The treatment of adenomyosis-induced ovarian hyperstimulation syndrome with leuprolide Cong YE 1, Bo ZHONG 1, Hui XU 2, Tong JIA 3, Hongling GUO 1 ✉ 1 Department of Gynecology, First People’s Hospital of Taicang City, Taicang, China; 2 Department of Ultrasound, First People’s Hospital of Taicang City, Taicang, China; 3 Department of Reproductive Health, Taicang Maternal and Child Health and Family Planning Service Center, Taicang, China

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (4)

Source provenance

europepmc
last seen: 2026-09-19T06:15:14.566301+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-09-19T06:10:57.900638+00:00
unpaywall
last seen: 2026-09-19T06:31:22.526400+00:00
License: CC0 · commercial use OK